MedTrace Logo

Combination Deferasirox and Deferiprone for Severe Iron Overload in Thalassemia

NCT01709032 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2019-03-06

Study results available
· View outcomes & findings →

Summary

We hypothesize that the combination treatment with deferasirox and deferiprone will be well tolerated and will result in significant improvement in cardiac and liver iron levels.

Conditions

  • Thalassemia Major With Severe Transfusional Iron Overload

Interventions

DRUG

Deferasirox and deferiprone

Sponsors & Collaborators

Principal Investigators

  • Janet L Kwiatkowski, MD, MSCE · Children's Hospital of Philadlephia

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-09-30
Primary Completion
2015-08-01
Completion
2017-08-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01709032 on ClinicalTrials.gov